The adoptive transfer of antigen-specific T cells that have been expanded ex vivo is being actively pursued to treat infections and malignancy in humans. The T cell populations that are available for adoptive immunotherapy include both effector memory and central memory cells, and these differ in phenotype, function, and homing. The efficacy of adoptive immunotherapy requires that transferred T cells persist in vivo, but identifying T cells that can reproducibly survive in vivo after they have been numerically expanded by in vitro culture has proven difficult. Here we show that in macaques, antigen-specific CD8+ T cell clones derived from central memory T cells, but not effector memory T cells, persisted long-term in vivo, reacquired phenotypic and functional properties of memory T cells, and occupied memory T cell niches. These results demonstrate that clonally derived CD8+ T cells isolated from central memory T cells are distinct from those derived from effector memory T cells and retain an intrinsic capacity that enables them to survive after adoptive transfer and revert to the memory cell pool. These results could have significant implications for the selection of T cells to expand or to engineer for adoptive immunotherapy of human infections or malignancy.
Carolina Berger, Michael C. Jensen, Peter M. Lansdorp, Mike Gough, Carole Elliott, Stanley R. Riddell
Title and authors | Publication | Year |
---|---|---|
Chimeric Antigen Receptor Therapy for Cancer
DM Barrett, N Singh, DL Porter, SA Grupp, CH June |
Annual Review of Medicine | 2014 |
Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells
M Bleakley, S Heimfeld, LA Jones, C Turtle, D Krause, SR Riddell, W Shlomchik |
Biology of Blood and Marrow Transplantation | 2014 |
Advances in Experimental Medicine and Biology
C DeRenzo, S Gottschalk |
Advances in experimental medicine and biology | 2014 |
Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions
P Kesarwani, AA Al-Khami, G Scurti, K Thyagarajan, N Kaur, S Husain, Q Fang, OS Naga, P Simms, G Beeson, C Voelkel-Johnson, E Garrett-Mayer, CC Beeson, MI Nishimura, S Mehrotra |
Cancer research | 2014 |
Elimination of Progressive Mammary Cancer by Repeated Administrations of Chimeric Antigen Receptor-Modified T Cells
A Globerson-Levin, T Waks, Z Eshhar |
Molecular Therapy | 2014 |
Engineered T cells for cancer treatment
U Anurathapan, AM Leen, MK Brenner, JF Vera |
Cytotherapy | 2014 |
Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype
R Gomez-Eerland, B Nuijen, B Heemskerk, N Rooij, JH van Berg, JH Beijnen, W Uckert, P Kvistborg, TN Schumacher, JB Haanen, A Jorritsma |
Human Gene Therapy Methods | 2014 |
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy
DM Barrett, N Singh, X Liu, S Jiang, CH June, SA Grupp, Y Zhao |
Cytotherapy | 2014 |
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
C Jin, D Yu, V Hillerdal, AC Wallgren, A Karlsson-Parra, M Essand |
Molecular Therapy — Methods & Clinical Development | 2014 |
Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
L Li, HT Kim, A Nellore, N Patsoukis, V Petkova, S McDonough, I Politikos, S Nikiforow, R Soiffer, JH Antin, K Ballen, C Cutler, J Ritz, VA Boussiotis |
Blood Cancer Journal | 2014 |
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches
A Rambaldi, E Biagi, C Bonini, A Biondi, M Introna |
Leukemia | 2014 |
Antigen-Specific Culture of Memory-like CD8 T Cells for Adoptive Immunotherapy
AJ Litterman, DM Zellmer, RS LaRue, SC Jameson, DA Largaespada |
Cancer immunology research | 2014 |
Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation
M Keller, C Bollard |
ImmunoTargets and Therapy | 2014 |
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
H Fujiwara |
Pharmaceuticals (Basel, Switzerland) | 2014 |
Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands in myeloid leukemia cells by TCR-transgenic T cells
R Klar, S Schober, M Rami, S Mall, J Merl, SM Hauck, M Ueffing, A Admon, J Slotta-Huspenina, M Schwaiger, S Stevanović, RA Oostendorp, DH Busch, C Peschel, AM Krackhardt |
Leukemia Supplements | 2014 |
Progress and prospects for engineered T cell therapies
W Qasim, AJ Thrasher |
British Journal of Haematology | 2014 |
Adoptive Immunotherapy for Cancer or Viruses
MV Maus, JA Fraietta, BL Levine, M Kalos, Y Zhao, CH June |
Annual Review of Immunology | 2014 |
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Y Xu, M Zhang, CA Ramos, A Durett, E Liu, O Dakhova, H Liu, CJ Creighton, AP Gee, HE Heslop, CM Rooney, B Savoldo, G Dotti |
Blood | 2014 |
Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells
M Wölfl, PD Greenberg |
Nature Protocols | 2014 |
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
B Thaci, CE Brown, E Binello, K Werbaneth, P Sampath, S Sengupta |
Neuro-Oncology | 2014 |
A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells
M Cartellieri, S Koristka, C Arndt, A Feldmann, S Stamova, M Bonin, K Töpfer, T Krüger, M Geib, I Michalk, A Temme, M Bornhäuser, D Lindemann, G Ehninger, MP Bachmann |
PloS one | 2014 |
Homeostatic expansion as a barrier to lymphocyte depletion strategies:
NA Zwang, LA Turka |
Current Opinion in Organ Transplantation | 2014 |
The role of CD4+ T cells in BKV-specific T cell immunity
BJ Weist, M Schmueck, H Fuehrer, A Sattler, P Reinke, N Babel |
Medical Microbiology and Immunology | 2014 |
Anticancer Tc9 cells
Y Lu, Q Wang, Q Yi |
OncoImmunology | 2014 |
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
H Shi, M Sun, L Liu, Z Wang |
Molecular Cancer | 2014 |
Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
M Jonnalagadda, A Mardiros, R Urak, X Wang, LJ Hoffman, A Bernanke, WC Chang, W Bretzlaff, R Starr, S Priceman, JR Ostberg, SJ Forman, CE Brown |
Molecular Therapy | 2014 |
Advances in T-cell therapy for ALL
SA Grupp |
Best Practice & Research Clinical Haematology | 2014 |
Adoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset Composition:
SR Riddell, D Sommermeyer, C Berger, LS Liu, A Balakrishnan, A Salter, M Hudecek, DG Maloney, CJ Turtle |
The Cancer Journal | 2014 |
CD19-CAR Trials:
CA Ramos, B Savoldo, G Dotti |
The Cancer Journal | 2014 |
Metabolic Engineering of Salmonella Vaccine Bacteria To Boost Human V 2V 2 T Cell Immunity
G Workalemahu, H Wang, KJ Puan, MH Nada, T Kuzuyama, BD Jones, C Jin, CT Morita |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells
C Berger, D Sommermeyer, M Hudecek, M Berger, A Balakrishnan, PJ Paszkiewicz, PL Kosasih, C Rader, SR Riddell |
Cancer immunology research | 2014 |
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
M Hudecek, D Sommermeyer, PL Kosasih, A Silva-Benedict, L Liu, C Rader, MC Jensen, SR Riddell |
Cancer immunology research | 2014 |
Chemokines as Novel and Versatile Reagents for Flow Cytometry and Cell Sorting
ML le Brocq, AR Fraser, G Cotton, K Woznica, CV McCulloch, KD Hewit, CS McKimmie, RJ Nibbs, JD Campbell, GJ Graham |
Journal of immunology (Baltimore, Md. : 1950) | 2014 |
Nature Biotechnology's academic spinouts of 2013.
Bouchie A, Allison M, Webb S, DeFrancesco L |
Nature Biotechnology | 2014 |